Medicenna Therapeutics Corp.

TSX:MDNA Canada Healthcare — Biotechnology

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develo…

15 employees medicenna.com

Click to toggle · Cmd+Click for exclusive

Results 2026-06-26

Open PDF

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

News release - English.pdf

Results 2026-06-25

Open PDF

Annual information form - English.pdf

Results 2026-06-25

Open PDF

Annual MD&A - English.pdf

Results 2026-06-25

Open PDF

Audited annual financial statements – English.pdf

News 2026-06-11

Open PDF

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

News release - English.pdf

Transactions 2026-06-03 Financing

Material document(s).pdf

Transactions 2026-06-03 Financing

Open PDF

Medicenna Therapeutics Corp. Announces Closing of Previously-Announced Marketed Public Offering of Units

Material change report - English.pdf

News 2026-06-03

Open PDF

Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

News release - English.pdf

Ownership 2026-06-02

5 insiders · +$278k net

Insider trading – 2026-06-02

5 insiders · +$278k net

Transactions 2026-05-28 Financing

Open PDF

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

News release - English.pdf

Transactions 2026-05-22 Financing

Open PDF

Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

News release - English.pdf

Transactions 2026-05-22 Financing

Underwriting or agency agreements (or amendment thereto).pdf

Transactions 2026-05-22 Financing

Prospectus (non pricing) supplement (other than ATM) – English.pdf

Transactions 2026-05-19 Financing

Open PDF

Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

News release - English.pdf

Transactions 2026-05-13 Financing

Open PDF

Medicenna Announces the Launch of a Marketed Public Offering of Securities

News release - English.pdf

News 2026-05-12

Open PDF

Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma

News release - English.pdf

News 2026-04-30

Open PDF

Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026

News release - English.pdf

Results 2026-04-21

Open PDF

Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026

News release - English.pdf

News 2026-04-14

Open PDF

Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

News release - English.pdf

News 2026-03-18

Open PDF

Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026

News release - English.pdf

Results 2026-02-13 Financials

Open PDF

Interim MD&A - English.pdf

Results 2026-02-13 Financials

Open PDF

Interim financial statements/report – English.pdf

Results 2026-01-15

Open PDF

Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook

News release - English.pdf

News 2025-12-16